FDA warns Wholesale Peptide that its website sells Prostamax and Gonadorelin as unapproved new drugs.
What happened
FDA reviewed the company's website, wholesalepeptide.com, in May 2026 rather than conducting an inspection. The agency found pages for Prostamax and Gonadorelin that describe them as treating prostate inflammation and enlarged prostate and as affecting testosterone and testes function, which makes them drugs. FDA says no approved application exists for either product, so they are unapproved new drugs and cannot be sold across state lines.
What FDA found
Prostamax and Gonadorelin are drugs because the website says they treat disease and affect how the body works.
Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1); 21 CFR 201.128Neither product is generally recognized as safe and effective for its labeled use, so both are 'new drugs'.
Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)Neither product has an FDA-approved application, yet the company offers them for sale.
Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)Offering these unapproved drugs for sale and shipping them across state lines is prohibited.
Sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)Labels saying 'Research Use Only' and 'not for human consumption' do not override the website claims that the products are meant for human use as drugs.
21 CFR 201.128
What FDA wants
FDA tells the company to investigate the root causes, fix the violations, and send a written response with the steps taken and documentation within 15 business days, citing reference number 729447.
Who should pay attention
- online peptide and supplement sellers who make health claims
- clinics and researchers buying peptides from websites
- brands relying on 'research use only' disclaimers
This is a summary. Read the original letter on fda.gov.